WHAT'S CONFIRMED
- ▸Most FDA scientific staff opposed the policy to ease access to unproven peptide drugs. — PBS NewsHour Health, Reason
NOT REPORTED ELSEWHERE
- ▸FDA scientific staff had limited input in drafting the policy, according to six people familiar with its development. — PBS NewsHour Health